llms.txt
Compare with other sites' llms.txt files →# Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways
> Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways - Healthcare Publication
- Base URL: https://www.targetedonc.com
- Generated: 2026-11-10T00:12:02.220Z
- Content updates: multiple times daily
## Content Access for AI Agents
This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.
**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response
**Example request:**
```
curl -H "Accept: text/markdown" https://www.targetedonc.com/view/article-slug
```
**YAML frontmatter schema** (returned with every Markdown response):
| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |
**Discovery headers** (included on all responses):
- `Link: <https://www.targetedonc.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.targetedonc.com/llms.txt` — Explicit discovery header
## Usage Policy
- Robots policy: [https://www.targetedonc.com/robots.txt](https://www.targetedonc.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.
## Content Categories
- [10th Anniversary](https://www.targetedonc.com/10th-anniversary)
- [CCC Elevate](https://www.targetedonc.com/ccc-elevate)
- [Case Based Peer Perspectives](https://www.targetedonc.com/case-based-peer-perspectives)
- [Case-Based Roundtable™](https://www.targetedonc.com/case-based-roundtable-series)
- [Clinical](https://www.targetedonc.com/clinical)
- [Clinical Trials](https://www.targetedonc.com/clinical-trials)
- [Conference News](https://www.targetedonc.com/conference)
- [Expert Perspective Tumor Board](https://www.targetedonc.com/expert-perspective-tumor-board)
- [Interviews](https://www.targetedonc.com/interviews)
- [Investigator Perspectives](https://www.targetedonc.com/investigator-perspectives)
- [News](https://www.targetedonc.com/news)
- [Oncology Icons](https://www.targetedonc.com/oncology-icons)
- [Podcasts](https://www.targetedonc.com/podcasts)
- [Precision Medicine](https://www.targetedonc.com/precision-medicine)
- [Press Releases](https://www.targetedonc.com/press-releases)
- [Publications](https://www.targetedonc.com/publications)
- [Sponsored Content](https://www.targetedonc.com/sponsored)
- [Video Programs](https://www.targetedonc.com/video-programs)
## Featured Content
- [Comparing Treatment Approaches in Second-Line Metastatic ccRCC](https://www.targetedonc.com/view/comparing-treatment-approaches-in-second-line-metastatic-ccrcc): During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequen...
- [Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC](https://www.targetedonc.com/view/imneskibart-activity-ici-refractory-melanoma-nsclc): Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lun...
- [Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care](https://www.targetedonc.com/view/dr-iyer-on-digitizing-nccn-guidelines-ai-point-of-care-nanets): Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care acces...
- [FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer](https://www.targetedonc.com/view/gedatolisib-snda-fda-acceptance-pik3ca-mutant-breast-cancer): The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of...
- [Benzopyran-Based Small Molecule Granted FDA Orphan Drug Status in AML](https://www.targetedonc.com/view/cantrixil-orphan-drug-designation-aml): The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML)...
- [Pembrolizumab Plus SBRT Fails to Improve EFS in Unresected Early-Stage NSCLC](https://www.targetedonc.com/view/pembrolizumab-sbrt-early-stage-nsclc-keynote-867-phase-3): In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase...
- [Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs](https://www.targetedonc.com/view/dr-dasari-on-prrt-alpha-emitters-trials-neuroendocrine-tumors-nanets): Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
- [NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit](https://www.targetedonc.com/view/nets-year-in-review-rlt-advances-as-combo-strategies-and-icis-show-limited-benefit-nanets): Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing...
- [Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate](https://www.targetedonc.com/view/real-world-data-reveal-factors-linked-to-myeloid-neoplasm-risk-after-lutetium-lu-177-dotatate): Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET anal...
- [Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers](https://www.targetedonc.com/view/dr-chauhan-on-oncolytic-virus-svv-001-in-neuroendocrine-cancers-nanets): Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
## Feeds and Indexes
- [RSS Feed](https://www.targetedonc.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.targetedonc.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.targetedonc.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.targetedonc.com/authors): Browse all contributors and their published work